Nirmatrelvir; Ritonavir Patent Expiration
Nirmatrelvir; Ritonavir is Used for treating mild-to-moderate COVID-19 in high-risk adults to prevent progression to severe outcomes like hospitalization or death. It was first introduced by Pfizer Inc
Nirmatrelvir; Ritonavir Patents
Given below is the list of patents protecting Nirmatrelvir; Ritonavir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Paxlovid (copackaged) | US11541034 | Nitrile-containing antiviral compounds | Oct 31, 2041 | Pfizer |
| Paxlovid (copackaged) | US11351149 | Nitrile-containing antiviral compounds | Aug 05, 2041 | Pfizer |
Nirmatrelvir; Ritonavir's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List